NO991096L - Nye fremgangsmÕter - Google Patents

Nye fremgangsmÕter

Info

Publication number
NO991096L
NO991096L NO991096A NO991096A NO991096L NO 991096 L NO991096 L NO 991096L NO 991096 A NO991096 A NO 991096A NO 991096 A NO991096 A NO 991096A NO 991096 L NO991096 L NO 991096L
Authority
NO
Norway
Prior art keywords
new procedures
idoxifene
treatment
cardiovascular disease
new method
Prior art date
Application number
NO991096A
Other languages
English (en)
Other versions
NO991096D0 (no
Inventor
Jeremy N Bradbeer
Maxine Gowen
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of NO991096D0 publication Critical patent/NO991096D0/no
Publication of NO991096L publication Critical patent/NO991096L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

Det beskrives en ny metode for behandling av kardiovaskulær sykdom hos postmenopausale kvinner. Idoxifene er den foretrukne forbindelse.
NO991096A 1996-09-06 1999-03-05 Nye fremgangsmÕter NO991096L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2543996P 1996-09-06 1996-09-06
US5066697P 1997-06-24 1997-06-24
PCT/US1997/015475 WO1998009619A1 (en) 1996-09-06 1997-09-03 Novel methods

Publications (2)

Publication Number Publication Date
NO991096D0 NO991096D0 (no) 1999-03-05
NO991096L true NO991096L (no) 1999-03-05

Family

ID=26699738

Family Applications (2)

Application Number Title Priority Date Filing Date
NO991097A NO991097D0 (no) 1996-09-06 1999-03-05 Nye fremgangsmÕter
NO991096A NO991096L (no) 1996-09-06 1999-03-05 Nye fremgangsmÕter

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO991097A NO991097D0 (no) 1996-09-06 1999-03-05 Nye fremgangsmÕter

Country Status (16)

Country Link
EP (2) EP0927029A4 (no)
JP (2) JP2002515046A (no)
KR (2) KR20000068473A (no)
CN (2) CN1236313A (no)
AR (1) AR008155A1 (no)
AU (2) AU4409797A (no)
BR (2) BR9711676A (no)
CA (2) CA2264943A1 (no)
CO (2) CO5070658A1 (no)
CZ (1) CZ76699A3 (no)
IL (1) IL128645A0 (no)
NO (2) NO991097D0 (no)
PL (2) PL332278A1 (no)
TR (2) TR199900506T2 (no)
TW (1) TW411273B (no)
WO (2) WO1998009619A1 (no)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5749998A (en) * 1997-02-11 1998-08-26 Novo Nordisk A/S Methods for treatment or prophylaxis of menopausal symptoms
GB9827121D0 (en) * 1998-12-09 1999-02-03 Orion Corp Agent for lowering endothelin levels
DE19905961A1 (de) * 1999-02-12 2000-08-17 Stefan Neubauer Verwendung von Östrogenen zur Behandlung der Herzinsuffizienz
US6528681B2 (en) * 2000-04-05 2003-03-04 Bristol-Meyers Squibb Pharma Company Halogenated triphenylethylene derivatives as selective estrogen receptor modulators
TWI303990B (en) 2000-10-17 2008-12-11 Pfizer Prod Inc New use of estrogen agonists/antagonists for improving vascular health

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2196003A (en) * 1986-09-11 1988-04-20 Nat Res Dev Iodo-and bromo-tamoxifen derivatives
ES2112994T3 (es) * 1992-09-15 1998-04-16 Merrell Pharma Inc Analogos de clomifeno no metabolizables utilizados en el tratamiento de tumores resistentes al tamoxifeno.
US6197789B1 (en) * 1995-06-07 2001-03-06 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
US5681835A (en) * 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
US5604248A (en) * 1994-05-05 1997-02-18 Eli Lilly And Company Method for minimizing the uterotrophic effect of tamoxifen and tamoxifen analogs
US5470883A (en) * 1994-05-23 1995-11-28 Stromberg; Brent V. Method of treating peripheral vasoconstriction with tamoxifen citrate
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
US6069175A (en) * 1996-11-15 2000-05-30 Pfizer Inc. Estrogen agonist/antagonists treatment of atherosclerosis

Also Published As

Publication number Publication date
TW411273B (en) 2000-11-11
WO1998009619A1 (en) 1998-03-12
AR008155A1 (es) 1999-12-09
PL332278A1 (en) 1999-08-30
JP2002515047A (ja) 2002-05-21
TR199900504T2 (xx) 1999-06-21
WO1998009519A1 (en) 1998-03-12
KR20000068473A (ko) 2000-11-25
JP2002515046A (ja) 2002-05-21
CO4920218A1 (es) 2000-05-29
CO5070658A1 (es) 2001-08-28
NO991097L (no) 1999-03-05
CN1236299A (zh) 1999-11-24
NO991097D0 (no) 1999-03-05
AU4247397A (en) 1998-03-26
NO991096D0 (no) 1999-03-05
BR9711676A (pt) 1999-08-24
EP0927029A4 (en) 2001-06-13
CA2264943A1 (en) 1998-03-12
EP0929216A4 (en) 2001-04-04
CN1236313A (zh) 1999-11-24
EP0927029A1 (en) 1999-07-07
EP0929216A1 (en) 1999-07-21
CZ76699A3 (cs) 1999-08-11
CA2264775A1 (en) 1998-03-12
IL128645A0 (en) 2000-01-31
PL332038A1 (en) 1999-08-16
AU4409797A (en) 1998-03-26
BR9711681A (pt) 1999-08-24
KR20000068472A (ko) 2000-11-25
TR199900506T2 (xx) 1999-07-21

Similar Documents

Publication Publication Date Title
EA199700170A1 (ru) Способ получения некоторых азациклогексапетидов
NO993247L (no) Fremgangsmåte for fremstilling av tolterodin
NO179250C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktiv (+)--(2,3-dimetoksyfenyl)-1-[2-(4-fluorfenyl)etylÅ-4-piperidinmetanol
ES2172587T3 (es) Composicion que comprende morfina, polipirrolidona y poli-oxido de alquileno.
PL332432A1 (en) Oxadiazoles, method of obtaining them as well as their application as therapeutic agents
ATE318845T1 (de) Therapeutische multispezifische verbindungen, die antikörper gegen den fcalpha-rezeptor enthalten
NO931780L (no) Applikator for innf!ring av en kremtypesubstans i en kvinnes vagina
NO991096L (no) Nye fremgangsmÕter
NO901383L (no) Maskin for automatisk anbringelse av myk pakning.
ZA9783B (en) Novel medical use
SE9501881D0 (sv) New pharmacological use of AII-receptor antagonists
ATE229326T1 (de) Therapie von depressionen
DE59709922D1 (de) Pflaster zur transdermalen anwendung von pergolid
NO984245D0 (no) Nasal administrasjon av midler for behandling av emesis med forsinket begynnelse
ATE330604T1 (de) Behandlung von manischen erkrankungen
NO973366L (no) Fremgangsmåte for behandling av multippel sklerose
NO20000961L (no) Nye vevs-spesifikke calpainer, samt fremgangsmåte for fremstilling og anvendelse derav
FR2759906B1 (fr) Utilisation de milnacipran et de ses derives pour la preparation d'un medicament destine au traitement de certaines maladies psychiatriques
DE69729201T2 (de) Sulfonfluoride zur behandlung von der alzheimerischen krankheit
DE69609954D1 (de) Verfahren zur herstellung von 2-arylbenz(ox,thi,imid)azolen und von 2-aminoaryl aminobenz(ox,thi,imid)azolen
DE69624566D1 (de) Behandlung der anorexie
NO990436L (no) FremgangsmÕte for behandling av bipolar forstyrrelse
SE9500897D0 (sv) The pharmacological use of certain cystine derivatives
NO972605L (no) Ny fremgangsmåte for fremstilling av ranitidin
NO20006382L (no) Fremgangsmåte for behandling av organofosfatforgiftning

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application